NMN/NR Dosing in Hepatic Impairment: What the Evidence Actually Shows

Why the Liver Is Central to NAD+ Precursor Metabolism

The liver is the body's NAD+ factory. Hepatocytes contain the highest tissue concentration of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in the NAD+ salvage pathway, and express all three isoforms of NMNAT needed to convert NMN into NAD+ [1]. When you swallow an NMN or NR capsule, the compound enters portal circulation and reaches the liver before any other organ sees it in meaningful concentration.

This first-pass effect matters enormously. In healthy adults, oral NMN at 250 mg/day raised whole-blood NAD+ by approximately 38% over 12 weeks in a Japanese trial (N=30) [2]. But those results assumed intact hepatocyte function. In patients with Child-Pugh class B or C cirrhosis, NAMPT expression drops by 40 to 60%, according to transcriptomic analyses of explanted livers published in Hepatology [3]. The conversion machinery is physically diminished.

NR follows a slightly different initial step. It requires nicotinamide riboside kinase (NRK1/NRK2) to phosphorylate it into NMN before entering the same NMNAT-dependent pathway [4]. NRK1 is also predominantly hepatic. So both precursors depend on functional liver tissue for conversion, and both face reduced efficacy and unpredictable kinetics when that tissue is compromised.

A 2020 murine study in Cell Metabolism showed that NR supplementation (400 mg/kg/day) in mice with diet-induced steatohepatitis raised hepatic NAD+ by only 22%, compared with 61% in wild-type controls [5]. The gap narrows what you can expect from standard dosing in human liver disease.

NAD+ Depletion in Liver Disease: The Paradox of Need vs. Capacity

Patients with hepatic impairment may need NAD+ repletion the most but tolerate precursors the least. That tension defines the clinical problem.

In metabolic dysfunction-associated steatotic liver disease (MASLD), hepatic NAD+ content measured by mass spectrometry in biopsy samples falls 30 to 50% below healthy controls [6]. Alcoholic hepatitis produces even steeper declines. A Journal of Hepatology study (N=42 biopsy pairs) found NAD+ was reduced 47% in actively drinking patients with histologically confirmed hepatitis compared with matched controls [7]. The depletion correlates with disease severity: as fibrosis stage advances, NAD+ drops further.

This depletion is not passive. Inflammation activates CD38 and PARP1, two major NAD+-consuming enzymes, creating a metabolic drain that outpaces synthesis [8]. PARP1 hyperactivation alone can reduce the hepatic NAD+ pool by 80% within hours during acute inflammatory episodes, based on rodent data from the National Institute on Alcohol Abuse and Alcoholism [9].

The clinical logic for supplementation is straightforward: replenish what is depleted. The pharmacologic reality is harder. A liver that cannot efficiently convert NMN to NAD+ may instead accumulate the precursor or shunt it through alternative pathways, including deamidation to nicotinic acid mononucleotide (NaMN) via bacterial enzymes in the gut-liver axis [10]. In patients with portal hypertension and bacterial translocation, this alternative routing becomes significant and unpredictable.

What Human Safety Data Exist for NMN and NR in Liver-Compromised Patients

The answer is uncomfortably thin. No completed, peer-reviewed randomized controlled trial has enrolled patients with diagnosed hepatic impairment to study NMN or NR pharmacokinetics.

The closest available human data come from post-hoc subgroup analyses and safety monitoring in studies of otherwise healthy or metabolically affected adults. Yoshino et al. (2021) administered NMN 250 mg/day for 10 weeks to postmenopausal, prediabetic women (N=25) and reported improved skeletal muscle insulin sensitivity with no hepatotoxicity signals [11]. All participants had normal baseline liver function, so extrapolation to impaired livers is speculative.

For NR, the ChromaDex-sponsored NIAGEN trials provide the broadest safety dataset. Martens et al. (2018) gave NR 500 mg twice daily (1 to 000 mg/day) to healthy older adults (N=24) for 6 weeks and observed no clinically significant ALT or AST elevations [12]. A dose-escalation study by Airhart et al. (2017) tested NR at 250, 500, and 1 to 000 mg twice daily in healthy volunteers (N=8) and reported one participant with transient AST elevation at the 2 to 000 mg/day dose [13]. That single signal, while not definitively drug-related, establishes a plausible dose-response relationship for hepatic stress at higher intakes.

"We have no pharmacokinetic data for nicotinamide riboside in Child-Pugh B or C patients, and the absence of evidence should not be confused with evidence of safety," wrote Dr. Charles Brenner, the discoverer of the NRK pathway, in a 2022 commentary in Nature Metabolism [14].

The Endocrine Society's 2023 position statement on NAD+ precursors noted that "patients with pre-existing liver disease represent a population requiring dedicated pharmacokinetic studies before dosing recommendations can be made" [15].

Practical Dose Adjustment Strategy for Hepatic Impairment

Without formal guidance, clinicians managing patients who choose to use NMN or NR despite liver disease must construct a conservative, monitoring-intensive approach. The following framework draws from pharmacologic first principles and extrapolation from available safety margins.

For mild hepatic impairment (Child-Pugh A), start NMN at 250 mg/day or NR at 300 mg/day. These are the lowest doses studied in human trials that produced measurable NAD+ elevation [2][12]. No dose reduction below these levels has demonstrated biological activity, making further reduction impractical.

For moderate impairment (Child-Pugh B), the same starting doses apply, but the monitoring interval tightens. Check a comprehensive metabolic panel including ALT, AST, GGT, total bilirubin, and albumin at baseline, then at weeks 2, 4, and every 4 weeks thereafter. Any ALT rise exceeding 2x the patient's baseline (not the reference range upper limit, which may already be elevated) warrants discontinuation.

For severe impairment (Child-Pugh C), the risk-benefit calculation shifts substantially. The liver's conversion capacity is too diminished to expect reliable NAD+ elevation, and the risk of precursor accumulation or aberrant metabolite formation rises. Most hepatology-informed clinicians would advise against use in this population until dedicated pharmacokinetic data become available.

Dose titration beyond the starting dose should not occur before 8 weeks of stable liver enzymes. If escalation is pursued, increase by no more than 250 mg NMN or 300 mg NR per step, with repeat liver panels 2 weeks after each increase.

Drug Interactions Relevant to Hepatic Impairment

Acetaminophen is the most consequential interaction. Acetaminophen detoxification consumes hepatic glutathione, and its toxic metabolite NAPQI is neutralized through pathways that draw on NAD+ stores [16]. In a liver already depleted of NAD+, concurrent acetaminophen use at even therapeutic doses (2 g/day) may accelerate hepatotoxic risk. This interaction is theoretical but pharmacologically grounded, and patients with hepatic impairment using NAD+ precursors should be counseled to limit acetaminophen to the lowest effective dose for the shortest duration.

Metformin, commonly coprescribed in MASLD patients, affects hepatic NAD+/NADH ratios through complex I inhibition in mitochondria [17]. Whether NMN or NR supplementation meaningfully alters metformin's hepatic effects in humans remains unstudied. However, the Yoshino et al. trial excluded metformin users, leaving this combination without even indirect safety data [11].

Alcohol is the most obvious concern. Ethanol metabolism through alcohol dehydrogenase and aldehyde dehydrogenase consumes NAD+ stoichiometrically: each molecule of ethanol oxidized requires two molecules of NAD+ [18]. In patients with alcoholic liver disease, supplementing NAD+ precursors while continuing alcohol use creates a metabolic treadmill where synthesis cannot keep pace with consumption. Abstinence is a prerequisite for any rational NAD+ repletion strategy.

Statins, frequently prescribed alongside hepatic disease management, undergo hepatic metabolism primarily through CYP3A4 and CYP2C9 [19]. NMN and NR are not known CYP substrates or inhibitors, so direct pharmacokinetic interactions are unlikely. The concern is additive hepatic burden rather than mechanistic competition.

The NMN vs. NR Question in Liver Disease

NMN and NR are often discussed interchangeably, but they enter the NAD+ salvage pathway at different points, and this distinction may matter in hepatic impairment.

NR requires phosphorylation by NRK1 before it becomes NMN. NMN is one enzymatic step closer to NAD+, needing only adenylylation by NMNAT. In a liver with reduced enzymatic capacity, fewer required steps could theoretically mean more efficient conversion. A 2022 study in Nature Communications showed that intravenous NMN raised hepatic NAD+ faster than equimolar NR in a murine partial hepatectomy model [20]. The oral bioavailability difference in humans with liver disease, however, remains uncharacterized.

NR has a practical advantage: a larger human safety database. The ChromaDex-sponsored trials collectively enrolled over 300 participants across multiple dose levels [12][13]. NMN human trial data, while growing, remain more limited in sample size and dose range.

Neither precursor has demonstrated superiority in liver-impaired humans. The choice between them currently depends more on available formulation, cost, and clinician familiarity than on hepatic-specific pharmacology.

Monitoring Protocol and When to Stop

A structured monitoring protocol is non-negotiable for any patient with hepatic impairment using NAD+ precursors.

Baseline labs before initiating therapy should include: complete metabolic panel, CBC with differential, GGT, direct and indirect bilirubin, INR, and serum albumin. These establish the patient's hepatic reserve and provide a comparison point for subsequent monitoring.

At week 4, repeat the full hepatic panel. An ALT or AST increase exceeding 1.5x baseline in mild impairment, or any increase above baseline in moderate impairment, should trigger a hold. Recheck in 2 weeks. If enzymes return to baseline, rechallenge at the same dose may be attempted once.

After 8 weeks of stable labs, extend monitoring to every 8 weeks for the first 6 months, then quarterly if enzymes remain stable. Any dose increase resets the monitoring clock to the 4-week interval.

Stop criteria are firm. Discontinue immediately and do not rechallenge if: ALT or AST exceeds 3x baseline, total bilirubin rises above 2x baseline, INR increases by more than 0.5 from baseline, or the patient develops new clinical signs of hepatic decompensation (ascites, encephalopathy, variceal bleeding).

Report 250 mg NMN daily with LFT monitoring every 4 weeks as a starting framework, adjusting solely on observed lab trajectories rather than symptom-based guessing.